Introduction: To identify the risk factors, characteristics and prognosis of patients treated with docetaxel-based chemotherapy for peritoneal carcinomatosis due to metastatic castrate-resistant prostate cancer (mCRPC). Methods: We retrospectively reviewed our series of mCRPC patients with peritoneal metastases treated with docetaxel-based chemotherapy between 2004 and 2010. Results: Six patients were identified from our institutions' internal cancer registry. Three out of these patients had been treated with laparoscopic radical prostatectomy (LRP). In addition to peritoneal metastases, other metastatic sites were mainly visceral. Only 1 patient developed bone metastases. Peritoneal carcinomatosis occurred mainly in patients with a high Gleason (= or >6) score since 5 out of our 6 patients had a Gleason score ≥7. All 6 patients were treated with docetaxel-based chemotherapy when they developed castration resistance. Five patients benefitted from chemotherapy according to their PSA or RECIST responses. Median survival from the start of docetaxel was 24.5 months. Conclusions: Our retrospective analysis suggests that peritoneal carcinomatosis occurs mainly in patients with a high Gleason score. It is also possible that tumor seeding occurs during LRP. Patients with peritoneal carcinomatosis resistant to castration seem to benefit from docetaxel-based chemotherapy.

Keywords:
Prostate cancer, Peritoneal metastases, Docetaxel-based chemotherapy
1.
Horwich A, Parker C, Bangma C, Kataja V: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:129-133.
2.
Hess KR, Varadhachary G, Taylor S, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer 2006;106:1624-1633.
3.
Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-583.
4.
Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK: Brain metastasis from prostate carcinoma. The M.D. Anderson Cancer Center experience. Cancer 2003;98:363-368.
5.
Hill VE, Brownstein S, Leonard BC, Jordan DR: Prostate adenocarcinoma presenting as a solitary choroidal metastasis. Can J Ophthalmol 1998;33:276-279.
6.
Obek C, Kural AR, Yaycioglu O, Kendiroglu G, Solok V: Metastatic adenocarcinoma of the prostate to the uvea as the initial presenting symptom in a 49-year-old man. Urology 2001;58:106.
7.
Simpson RH, Skalova A: Metastatic carcinoma of the prostate presenting as parotid tumour. Histopathology 1997;30:70-74.
8.
Huang HN, Huang SH: Ascites as an initial presentation of prostatic carcinoma: A case report. Clin Mol Med 2011;2:8-11.
9.
Obrist R, Wegmann W, Kiss D: Prostate cancer with an unusual course. Onkologie 1990;13:388-391.
10.
Kehinde EO, Abdeen SM, Al-Hunayan A, Ali Y: Prostate cancer metastatic to the omentum. Scand J Urol Nephrol 2002;36:225-227.
11.
Benedict S, Ahuja M, Mammen K: Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: a case report and review of literature. Indian J Urol 2010;26:287-288.
12.
Brehmer B, Makris A, Wellmann A, Jakse G: Solitary peritoneal carcinomatosis in prostate cancer (in German). Aktuelle Urol 2007;38:408-409.
13.
Lapoile E, Ballaïche G, Choudat L, Ley G, Slama JL: Ascite en rapport avec une extension métastatique d'un cancer de prostate: une localisation inhabituelle. EMC, Gastroentérol Clin Biol 2004;21:92.
14.
Zagouri F, Papaefthimiou M, Chalazonitis A, Antoniou N, Dimopoulos MA, Bamias A: Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease. Onkologie 2009;32:758-761.
15.
Hiyama Y, Kitamura H, Takahashi S, Masumori N, Shindo T, Tsujiwaki M, Mitsuhashi T, Hasegawa T, Tsukamoto T: Peritoneal dissemination of prostate cancer due to laparoscopic radical prostatectomy: a case report. J Med Case Rep 2011;5:355.
16.
Wynn SS, Nagabundi S, Koo J, Chin NW: Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med 2000;124:1074-1076.
17.
Grabstald H, Chabon A, McSherry C: Prostate cancer: unusual metastases 20 years after iodine-125 brachytherapy. J Urol 1995;154:203-204.
18.
Tannock IF, de Wit R, Berry W, Horti J, Pluzanska A, Chi K, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
19.
Petrylak D, Tangen CM, Hussain M, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
20.
Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:3343-3351.
21.
Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J: Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 2008;26:5261-5268.
22.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
23.
Shamseddine A, Farhat FS, Elias E, Khauli RB, Saleh A, Bulbul MA: High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study. Urol Int 2013;90:56-61.
24.
Heidenreich A, Witjes WPJ, Bjerklund-Johansen TE, Patel A, for the EAU Research Foundation: Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance. Urol Int 2012;89:30-38.
25.
Micali S, Celia A, Bove P, De Stefani S, Sighinolfi MC, Kavoussi LR, Bianchi G: Tumor seeding in urological laparoscopy: an international survey. J Urol 2004;171:2151-2154.
26.
Tsivian A, Sidi AA: Port site metastases in urological laparoscopic surgery. J Urol 2003;169:1213-1218.
27.
De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147-1154.
28.
De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
29.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, The AFFIRM investigators: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
30.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.